Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Agios Pharmaceuticals, Inc. (AGIO)

Compare
27.40
-1.90
(-6.48%)
At close: April 1 at 4:00:01 PM EDT
26.70
-0.70
(-2.55%)
Pre-Market: 4:56:17 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
36,498
36,498
26,823
14,240
--
Cost of Revenue
4,165
4,165
2,881
1,704
--
Gross Profit
32,333
32,333
23,942
12,536
--
Operating Expense
458,070
458,070
415,429
401,583
378,418
Operating Income
-425,737
-425,737
-391,487
-389,047
-378,418
Net Non Operating Interest Income Expense
48,083
48,083
33,344
12,793
836
Other Income Expense
1,095,623
1,095,623
6,055
144,453
21,072
Pretax Income
717,969
717,969
-352,088
-231,801
-356,510
Tax Provision
44,244
44,244
--
--
--
Net Income Common Stockholders
673,725
673,725
-352,088
-231,801
1,604,715
Diluted NI Available to Com Stockholders
673,725
673,725
-352,088
-231,801
1,604,715
Basic EPS
11.86
11.86
--
-4.23
26.55
Diluted EPS
11.66
11.64
--
-4.23
26.55
Basic Average Shares
56,513.65
56,807.42
--
54,789.44
60,447.35
Diluted Average Shares
57,167.70
57,889.26
--
54,789.44
60,447.35
Total Operating Income as Reported
-425,737
-425,737
-391,487
-389,047
-378,418
Total Expenses
462,235
462,235
418,310
403,287
378,418
Net Income from Continuing & Discontinued Operation
673,725
673,725
-352,088
-231,801
1,604,715
Normalized Income
-347,884.57
-347,884.57
-352,088
-369,505
-363,149
Interest Income
48,083
48,083
33,344
12,793
836
Net Interest Income
48,083
48,083
33,344
12,793
836
EBIT
-425,737
-425,737
-391,487
-389,047
-378,418
EBITDA
-420,084
-420,084
-384,864
-380,483
-369,178
Reconciled Cost of Revenue
4,165
4,165
2,881
1,704
--
Reconciled Depreciation
5,653
5,653
6,623
8,564
9,240
Net Income from Continuing Operation Net Minority Interest
673,725
673,725
-352,088
-231,801
-356,510
Total Unusual Items Excluding Goodwill
1,089,136
1,089,136
--
137,704
6,639
Total Unusual Items
1,089,136
1,089,136
--
137,704
6,639
Normalized EBITDA
-1,509,220
-1,509,220
-384,864
-518,187
-375,817
Tax Rate for Calcs
0
0
--
--
--
Tax Effect of Unusual Items
67,526.43
67,526.43
--
--
--
12/31/2021 - 7/24/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RARE Ultragenyx Pharmaceutical Inc.
33.84
-6.55%
 
IRON Disc Medicine, Inc.
47.15
-5.02%
 
PTCT PTC Therapeutics, Inc.
46.60
-8.56%
 
BPMC Blueprint Medicines Corporation
85.94
-2.90%
 
KYMR Kymera Therapeutics, Inc.
25.24
-7.80%
 
VERA Vera Therapeutics, Inc.
22.02
-8.33%
 
DYN Dyne Therapeutics, Inc.
9.23
-11.76%
 
PTGX Protagonist Therapeutics, Inc.
46.88
-3.06%
 
IONS Ionis Pharmaceuticals, Inc.
27.26
-9.65%
 
INCY Incyte Corporation
60.91
+0.59%